Melillo L, Cascavilla N, Lombardi G, Carotenuto M, Musto P
Department of Hematology, Casa Sollievo della Sofferenza Hospital, Istituto di Ricovero e Cura a Carattere Scientifico S. Giovanni Rotondo, Italy.
Leukemia. 1992 Oct;6(10):1076-8.
Serum levels of beta 2-microglobulin (S-B2m) were analysed at diagnosis in 69 cases of acute myeloid leukemias (AML) as a possible prognostic indicator. S-B2m was correlated to various clinical and laboratory features and with respect to response to chemotherapy and following clinical outcome. S-B2m was found to be increased (greater than 3 mg/l) in 40.6% of tested patients and, in particular, in the monocytic variants (M4, M5) of AML (4.2 versus 2.3 mg/l, p less than 0.01). S-B-B2m values paralleled white blood cell count, serum lysozyme levels and expression of monocytic membrane markers at presentation, but no correlation was found with age, renal function or immunological myeloid antigens. Increased levels of S-B2m were associated with a lower likelihood of obtaining a complete remission (25 versus 58.5%, p less than 0.01), while in the multivariate analysis S-B2m greater than 3 mg/l and white blood cell count greater than 20 x 10(9)/l were independent variables significantly influencing disease-free survival in responsive patients (five years DFS for S-B2m greater than or less than 3 mg/l: 28 versus 62%, p less than 0.05). In conclusion, the measurement of S-B2m at diagnosis may have prognostic relevance in AML.
对69例急性髓系白血病（AML）患者在诊断时分析血清β2-微球蛋白（S-B2m）水平，将其作为一种可能的预后指标。S-B2m与各种临床和实验室特征相关，并与化疗反应及后续临床结果相关。在40.6%的受试患者中发现S-B2m升高（大于3mg/l），特别是在AML的单核细胞变异型（M4、M5）中（4.2对2.3mg/l，p<0.01）。S-B2m值与就诊时的白细胞计数、血清溶菌酶水平及单核细胞膜标志物表达平行，但与年龄、肾功能或免疫髓系抗原无相关性。S-B2m水平升高与获得完全缓解的可能性较低相关（25%对58.5%，p<0.01），而在多变量分析中，S-B2m大于3mg/l和白细胞计数大于20×10⁹/l是显著影响缓解患者无病生存的独立变量（S-B2m大于或小于3mg/l的5年无病生存率：28%对62%，p<0.05）。总之，诊断时测定S-B2m可能对AML具有预后意义。
